Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 814-217-0 | CAS number: 353258-35-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Remarks:
- Pilot study
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Evaluation of the maternal and developmental toxicity of the test substance was performed when administered to pregnant rats from around the time of implantation to the end of gestation.
- GLP compliance:
- no
Test material
- Reference substance name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
- Cas Number:
- 353258-35-2
- Molecular formula:
- C9H4ClF3N2O2
- IUPAC Name:
- 8-chloro-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxylic acid
1
- Specific details on test material used for the study:
- Test substance: IN-QEK31-011
Batch No.: SG0312574
Purity: 98.2%
Test animals
- Species:
- rat
- Strain:
- other: Crl:CD(SD)
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: 0.5% methylcellulose with 0.1% Tween 80
- Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- GD 6-20
- Frequency of treatment:
- Once daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 100 mg/kg bw/day
- Dose / conc.:
- 500 mg/kg bw/day
- Dose / conc.:
- 1 000 mg/kg bw/day
- No. of animals per sex per dose:
- 8 females per group
- Control animals:
- yes, concurrent vehicle
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Clinical signs of toxicity were evident at 1000 mg/kg/day and included dehydration (5 animals), hunched over appearance (4 animals), lethargy (3 animals), decreased muscle tone (4 animals), scant feces (2 animals), and prostrate and tremors (1 animal). One animal at 500 mg/kg/day was dehydrated.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- There were 5 animals found dead from GD 8 to 10 at 1000 mg/kg/day. The remaining 3 animals at this level were subsequently euthanized on GD 10 or 11due to adverse weight gain reductions and/or clinical signs of toxicity.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- There were treatment-related, statistically significant adverse effects observed on body weight parameters at ≥ 500 mg/kg/day. At 1000 mg/kg/day mean maternal body weights were reduced 11%-23% as compared to control group. During the first few days of dosing (GD 6-8) animals lost an average of 28 grams compared to an average gain of 12 grams for the control group. At 500 mg/kg/day, mean maternal body weights were up to 8% lower than control group throughout the study. These effects were slightly more pronounced towards the end of the study; terminal absolute and adjusted (minus products of conception) were 8% lower than control group. During the first few days of dosing (GD 6-8) animals at this level lost an average of 2 grams compared to an average gain of 12 grams for the control group. Reduced body weight gains persisted at this level resulting in mean overall (GD 6-21) absolute/adjusted body weight gains that were 20%/47% lower than control group, respectively. At 100 mg/kg/day, mean body weights were generally comparable to control group throughout the study; terminal absolute/adjusted body weights were within 3% of control group values. Mean body weight gains were 54% lower than control at this level during the first few days of dosing (GD 6-8). Some recovery was subsequently evident; mean overall absolute/adjusted body weight gains were within 9% of the control group value.
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- There were no treatment-related, statistically significant adverse effects observed on food consumption parameters at ≥ 500 mg/kg/day. At 1000 mg/kg/day, mean food consumption was 71%-75% lower than control from gestation day s 6-10. At 500 mg/kg/day, food consumption was reduced 11-22% as compared to control group throughout the study. Mean overall food consumption was 16% lower than control group at this level. At 100 mg/kg/day mean food consumption was 13% lower than control group during the first few days of dosing (GD 6-8). Thereafter, food consumption was up to 9% lower than control group. Mean overall food consumption was statistically significantly reduced (7% lower than control); however the magnitude was minimal and non-adverse at this level.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related, statistically significant effects observed on kidney weight parameters at any level tested. Kidney weights were not collected for animals that were euthanized prior to scheduled sacrifice (including all animals at 1000 mg/kg/day).
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Black discoloration of the glandular portion of the stomach was observed in 5/8 animals at 1000 mg/kg/day. There were no other maternal gross observations on this study.
Maternal developmental toxicity
- Total litter losses by resorption:
- no effects observed
Effect levels (maternal animals)
- Key result
- Remarks on result:
- other: Under the conditions of this study, there was no adverse maternal toxicity observed at 100 mg/kg/day.
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Details on embryotoxic / teratogenic effects:
- There were no totally resorbed litters observed on this study. There were no treatment-related effects on mean number of resorptions observed at any level tested. Data from animals at 1000 mg/kg/day was not available since these animals were either found dead or euthanized prior to scheduled sacrifice by gestation day 11. There were no statistically significant, treatment-related effects observed on mean fetal weight at any level tested. Data from animals at 1000 mg/kg/day was not available since these animals were either found dead or euthanized prior to scheduled sacrifice by gestation day 11. There were no treatment-related fetal anomalies observed on this study. Data from animals at 1000 mg/kg/day was not available since these animals were either found dead or euthanized prior to scheduled sacrifice by gestation day 11.
Effect levels (fetuses)
- Key result
- Remarks on result:
- other: There was no developmental toxicity observed at 500 mg/kg/day or lower.
Overall developmental toxicity
- Key result
- Developmental effects observed:
- no
Applicant's summary and conclusion
- Conclusions:
- Under the conditions of this study, there was no adverse maternal toxicity observed at 100 mg/kg/day. There was no developmental toxicity observed at 500 mg/kg/day or lower.
- Executive summary:
The objective of this study was to provide a preliminary evaluation of the maternal and developmental toxicity of the test substance when administered to pregnant rats from around the time of implantation to the end of gestation.
There were treatment-related and adverse effects on body weight and food consumption parameters at ≥500 mg/kg/day and maternal gross findings, clinical signs of toxicity and early mortality observed at 1000 mg/kg/day. There was no developmental toxicity observed at 500 mg/kg/day or lower. The mean number of corpora lutea, implantation sites, resorptions, and live fetuses, as well as sex ratio and fetal weight, were comparable across all groups. There were no test substance-related fetal external malformations or variations observed at any treatment level.
There were no surviving animals after gestation day 11 at 1000 mg/kg/day. Therefore, developmental toxicity at this level could not be properly assessed.
Under the conditions of this study, there was no adverse maternal toxicity observed at 100 mg/kg/day. There was no developmental toxicity observed at 500 mg/kg/day or lower.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.